Siri Tähtinen is a Principal Scientist and Group Leader at Genentech, where they investigate novel biology and therapeutic targets for treating inflammatory and autoimmune diseases. Siri's current research focuses on developing immunotherapeutic and vaccine modalities, emphasizing immunobiology and mechanism-of-action. Previously, Siri worked as a Postdoctoral Research Fellow at Genentech, where they studied various cancer vaccine platforms, and they completed a PhD in Biomedicine at the University of Helsinki, contributing to novel immunotherapies and resulting in intellectual property associated with TILT Biotherapeutics. Earlier experiences included roles as a Research Assistant at the University of Turku and a Summer Employee at Innotrac Diagnostics Oy.
Location
South San Francisco, United States